The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Interleukin-17 Receptor A Signaling in Transformed Enterocytes Promotes Early Colorectal Tumorigenesis
Open accessAbstract
Summary Interleukin-17A (IL-17A) is a proinflammatory cytokine linked to rapid malignant progression of colorectal cancer (CRC) and therapy resistance. IL-17A exerts its pro-tumorigenic activity through its type A receptor (IL-17RA). However, how IL-17RA engagement promotes colonic tumorigenesis is unknown, as IL-17RA is expressed in many cell types in the tumor microenvironment, including hematopoietic, fibroblastoid and epithelial cells. Here we show that IL-17RA signals directly within transformed colonic epithelial cells (enterocytes) to promote early tumor development. IL-17RA engagement activates ERK, p38 MAPK and NF-κB signaling and promotes the proliferation of tumorigenic enterocytes who just lost expression of the APC tumor suppressor. Although IL-17RA signaling also controls production of IL-6, this mechanism makes only a partial contribution to colonic tumorigenesis. Combined treatment with chemotherapy, which induces IL-17A expression, and an IL-17A neutralizing antibody enhanced the therapeutic responsiveness of established colon tumors. These findings establish IL-17A and IL-17RA as therapeutic targets in colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Self-citationInflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · cited 4×
“Organoid culture of small-intestinal crypts has been previously described (Sato et al., 2009).”
InfluentialKorn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Self-citationGrivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Self-citationWu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 1×
“Il6 / (Kopf et al., 1994) and CD45.”
Innate IL-17-producing cells: the sentinels of the immune system
Cua, D. J., & Tato, C. M. (2010) · Nature Reviews Immunology · doi:10.1038/nri2800 · Cited by 1,578
Ye, P., Rodriguez, F. H., Kanaly, S., Stocking, K. L., Schurr, J., Schwarzenberger, P., Oliver, P., Huang, W., Zhang, P., Zhang, J., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.519 · Cited by 1,521
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327 · cited 15×
“To understand how IL-17RA promotes colorectal tumorigenesis, we employed the CPC-APC model (Hinoi et al., 2007) as previously described (Grivennikov et al., 2012).”
InfluentialSelf-citationFunctional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP
Rodríguez, C. I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, A. F., & Dymecki, S. M. (2000) · Nature Genetics · doi:10.1038/75973 · Cited by 1,159
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
Tissue‐specific and inducible Cre‐mediated recombination in the gut epithelium
El Marjou, F., Janssen, K., Hung‐Junn Chang, B., Li, M., Hindie, V., Chan, L., Louvard, D., Chambon, P., Metzger, D., & Robine, S. (2004) · genesis · doi:10.1002/gene.20042 · Cited by 1,060
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946 · cited 3×
“This stands in marked contrast to the AOM+DSSCACmodel, where inflammation (DSS)-induced IL-6 signaling plays amajor role in tumorigenesis along with IL-11 (Bollrath et al., 2009; Grivennikov et al., 2009; Putoczki et al., 2013).”
Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 774
Regulation of inflammatory responses by IL-17F
Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y.-H., Schluns, K. S., Broaddus, R. R., Zhu, Z., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071978 · Cited by 739 · cited 3×
“These results indicate that although IL-17A neutralization might enhance colitis-associated mucosal injury (Yang et al., 2008) and therefore might not be suitable for the treatment of IBD or CAC, which occur in the context of ulcerative colitis, IL-17A neutralization is suitable for the treatment and prevention of spo…”
Tanaka, T., Kohno, H., Suzuki, R., Yamada, Y., Sugie, S., & Mori, H. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01386.x · Cited by 729
TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.020 · Cited by 726
TH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · cited 1×
“Elevated expression of IL-17 cytokines has been linked to resistance to both classical cytotoxic drugs and targeted therapeutics, such as the VEGF neutralizing antibody Avastin (Chung et al., 2013).”
Putoczki, T. L., Thiem, S., Loving, A., Busuttil, R. A., Wilson, N. J., Ziegler, P. K., Nguyen, P. M., Preaudet, A., Farid, R., Edwards, K. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.017 · Cited by 421
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
Self-citationAutocrine IL-6 Signaling: A Key Event in Tumorigenesis?
Grivennikov, S., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.020 · Cited by 368
Self-citationT helper 17 cells play a critical pathogenic role in lung cancer
Chang, S. H., Mirabolfathinejad, S. G., Katta, H., Cumpian, A. M., Gong, L., Caetano, M. S., Moghaddam, S. J., & Dong, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319051111 · Cited by 326 · cited 2×
“Il17a / and Il17ra / mice are also resistant to chemically induced skin cancer (He et al., 2012; Wang et al., 2010), and IL-17A promotes development of lung cancer in mice (Chang et al., 2014).”
Mouse Model of Colonic Adenoma-Carcinoma Progression Based on Somatic Apc Inactivation
Hinoi, T., Akyol, A., Theisen, B. K., Ferguson, D. O., Greenson, J. K., Williams, B. O., Cho, K. R., & Fearon, E. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2735 · Cited by 314
Self-citationEffect of IL-17A blockade with secukinumab in autoimmune diseases
Patel, D. D., Lee, D. M., Kolbinger, F., & Antoni, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202371 · Cited by 313
IL‐17‐producing γδ T cells and innate lymphoid cells
Sutton, C. E., Mielke, L. A., & Mills, K. H. G. (2012) · European Journal of Immunology · doi:10.1002/eji.201242569 · Cited by 275
Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis
Chae, W.-J., Gibson, T. F., Zelterman, D., Hao, L., Henegariu, O., & Bothwell, A. L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912675107 · Cited by 243
IL-17 family member cytokines: Regulation and function in innate immunity
Reynolds, J. M., Angkasekwinai, P., & Dong, C. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.10.002 · Cited by 235
IL-17 Enhances Tumor Development in Carcinogen-Induced Skin Cancer
Wang, L., Yi, T., Zhang, W., Pardoll, D. M., & Yu, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0775 · Cited by 185
Self-citationSong, X., Gao, H., Lin, Y., Yao, Y., Zhu, S., Wang, J., Liu, Y., Yao, X., Meng, G., Shen, N., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.018 · Cited by 185
Role of IL-17A in the development of colitis-associated cancer
Hyun, Y. S., Han, D. S., Lee, A. R., Eun, C. S., Youn, J., & Kim, H.-Y. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs106 · Cited by 182
Zhuang, Y., Peng, L., Zhao, Y., Shi, Y., Mao, X., Chen, W., Pang, K. C., Liu, X., Liu, T., Zhang, J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.010 · Cited by 168
Self-citationShen, F. W., Saga, Y., Litman, G., Freeman, G., Tung, J. S., Cantor, H., & Boyse, E. A. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.21.7360 · Cited by 160
A Protective Role by Interleukin-17F in Colon Tumorigenesis
Tong, Z., Yang, X. O., Yan, H., Liu, W., Niu, X., Shi, Y., Fang, W., Xiong, B., Wan, Y., & Dong, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034959 · Cited by 155
Feng, Y., Bommer, G. T., Zhao, J., Green, M. E., Sands, E., Zhai, Y., Brown, K., Burberry, A., Cho, K. R., & Fearon, E. R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.007 · Cited by 145
Self-citationAlshaker, H. A., & Matalka, K. Z. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-33 · Cited by 126
Feng, Y., Sentani, K., Wiese, A. B., Sands, E., Green, M. E., Bommer, G. T., Cho, K. R., & Fearon, E. R. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.013 · Cited by 110
Self-citationIL-17 Mediated Inflammation Promotes Tumor Growth and Progression in the Skin
He, D., Li, H., Yusuf, N., Elmets, C. A., Athar, M., Katiyar, S. K., & Xu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032126 · Cited by 105
The IL-17/IL-23 axis of inflammation in cancer: friend or foe?
Martín‐Orozco, N., & Dong, C. (2009) · PubMed · Cited by 73
Prevalence and clinical relevance of Th17 cells in patients with gastric cancer
Yamada, Y., Saito, H., & Ikeguchi, M. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.07.055 · Cited by 73
Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17
Dungan, L. S., & Mills, K. H. G. (2011) · Cytokine · doi:10.1016/j.cyto.2011.07.007 · Cited by 56
Vizio, B., Novarino, A., Giacobino, A., Cristiano, C., Prati, A., Ciuffreda, L., Montrucchio, G., & Bellone, G. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.553 · Cited by 53
Increased IL-17-producing CD4+ T cells in patients with esophageal cancer
Chen, D., Hu, Q., Mao, C., Jiao, Z., Wang, S., Yu, L., Xu, Y., Dai, D., Yin, L., & Xu, H. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2011.10.015 · Cited by 48
IL-17F deficiency inhibits small intestinal tumorigenesis in ApcMin/+ mice
Chae, W., & Bothwell, A. L. M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.09.016 · Cited by 44
The profile of Th17 subset in glioma
Hu, J., Mao, Y. Q., Li, M., & Lu, Y. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.03.015 · Cited by 27
Cited by
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
“Cytokines like IL-17 also can act directly on CRC cancer cells to provide them with resistance to a first line anti-CRC therapy with 5-FU (Wang et al., 2014) and inflammatory signaling targeting remaining tumor cell is an important driver of therapy resistance (Jinushi et al.”
BackgroundSelf-citationNF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Self-citationReparative inflammation takes charge of tissue regeneration
Karin, M., & Clevers, H. (2016) · Nature · doi:10.1038/nature17039 · Cited by 767
Self-citationImmunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
Self-citationChung, L., Thiele Orberg, E., Geis, A. L., Chan, J. L., Fu, K., DeStefano Shields, C. E., Dejea, C. M., Fathi, P., Chen, J., Finard, B. B., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.01.007 · Cited by 644
Metadata
- Authors
- Wang, K., Kim, M. K., Di Caro, G., Wong, J., Shalapour, S., Wan, J., Zhang, W., Zhong, Z., Sanchez-Lopez, E., Wu, L.-W., Taniguchi, K., Feng, Y., Fearon, E., Grivennikov, S. I., & Karin, M.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 41
- Issue
- 6
- Pages
- 1052-1063
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2081236127
- Cited by
- 341
- References
- 50
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.